Compare · ELV vs YDES
ELV vs YDES
Side-by-side comparison of Elevance Health Inc. (ELV) and YD Bio Limited (YDES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and YDES operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $84.97B, about 332.3x YDES ($255.7M).
- Over the past year, ELV is up 2.9% and YDES is down 73.1% - ELV leads by 75.9 points.
- ELV has been more active in the news (13 items in the past 4 weeks vs 2 for YDES).
- ELV has more recent analyst coverage (23 ratings vs 0 for YDES).
PerformanceELV+22.71%YDES-73.05%
2025-08-29+0.00%2026-06-03
- Company
- Elevance Health Inc.
- YD Bio Limited
- Price
- $391.27+0.64%
- $3.60+22.45%
- Market cap
- $84.97B
- $255.7M
- 1M return
- +5.19%
- -28.43%
- 1Y return
- +2.88%
- -73.05%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 13
- 2
- Recent ratings
- 23
- 0
ELV
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest ELV
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
- Director Schulman Amy W was granted 563 shares, increasing direct ownership by 258% to 781 units (SEC Form 4)
- Director Schneider Ryan M. was granted 563 shares, increasing direct ownership by 9% to 7,163 units (SEC Form 4)
- Director Peru Ramiro G was granted 563 shares, increasing direct ownership by 6% to 9,908 units (SEC Form 4)
- Director Neri Antonio F was granted 563 shares, increasing direct ownership by 11% to 5,488 units (SEC Form 4)
- Director Jallal Bahija was granted 563 shares, increasing direct ownership by 12% to 5,351 units (SEC Form 4)
- Director Hay Lewis Iii was granted 563 shares, increasing direct ownership by 5% to 12,070 units (SEC Form 4)
- Director Dixon Robert L Jr was granted 563 shares, increasing direct ownership by 5% to 10,885 units (SEC Form 4)
Latest YDES
- SEC Form EFFECT filed by YD Bio Limited
- SEC Form POS AM filed by YD Bio Limited
- YD Bio Limited Reports Full Year 2025 Financial Results
- SEC Form 20-F filed by YD Bio Limited
- Amendment: SEC Form 3 filed by new insider Lu Shao-Ta
- SEC Form 4 filed by Lu Shao-Ta
- SEC Form 4 filed by Chang Kochi
- SEC Form 3 filed by new insider Lu Shao-Ta
- SEC Form 3 filed by new insider Chang Kochi
- YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States